All In Biotech

Free tool

FAERS Monitor: Vosevi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209195 or its brand name (Vosevi, Sofosbuvir, Velpatasvir, Voxilaprevir). Reports on generic versions are filed under their own applications.

Reports

1,086

Serious

405

37% of reports

Hospitalization

81

Death reported

35

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue197
  • headache134
  • treatment failure115
  • drug ineffective108
  • nausea104
  • hepatitis c91
  • diarrhoea86
  • vomiting36
  • insomnia29
  • abdominal discomfort23
  • hepatocellular carcinoma22
  • product dose omission20
  • intentional dose omission19
  • pruritus19
  • asthenia18

Reports by year received

View as table
YearReports
201780
2018363
2019275
2020133
202172
202246
202340
202419
202543
202615

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,073 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis cSignal91147.1120.712,967
hepatocellular carcinomaSignal2256.237.11,135
treatment failureSignal11526.922.62,852
intentional dose omissionSignal1912.98.3197
product dose omissionSignal205.93.877
fatigueSignal1974.94.3631
headacheSignal1344.13.5326
abdominal discomfortSignal232.71.822
diarrhoeaSignal862.62.184
nauseaSignal1042.52.1100
insomniaSignal292.11.516
drug ineffective1081.61.324
vomiting361.51.15
pruritus191.00.60
asthenia180.90.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.